AMENDMENTS TO THE CLAIMS

1-12. (Cancelled)

13. (Currently Amended) A method of promoting ~~corneal~~ neuritogenesis of corneal nerves that are damaged, cut or defective by a corneal surgery or corneal disease, which comprises administering an effective amount of a Rho kinase inhibitor (ROCK inhibitor) which is selected from the group consisting of 2-chloro-6,7-dimethoxy-N-[5-1H-indazolyl]quinazoline-4-amine, N-(1-benzyl-4-piperidinyl)-1H-indazole-5-amine dihydrochloride, 4-[2-(2,3,4,5,6-pentafluorophenyl)acryloyl]cinnamic acid and fasudil hydrochloride to a subject in need of the promotion of the corneal neuritogenesis, wherein the corneal nerves in the subject are damaged, cut or defective by a corneal surgery or corneal disease.

14. (Withdrawn) A method of promoting extension of corneal nerve axon, which comprises administering an effective amount of Exoenzyme C3 or a ROCK inhibitor to a subject in need of the promotion of extension of the corneal nerve axon.

15. (Withdrawn) A method of recovering corneal sensitivity, which comprises administering an effective amount ofExoenzyme C3 or a ROCK inhibitor to a subject in need of the recovery of corneal sensitivity.

16. (Withdrawn) A method of treating dry eye, which comprises administering an effective amount of Exoenzyme C3 or a ROCK inhibitor to a subject affected with dry eye.

17. (Cancelled)

18. (Withdrawn) The method according to claim 14, wherein the ROCK inhibitor is selected from the group consisting of 2-chloro-6,7-dimethoxy-N-[5-1H-indazolyl]quinazoline-4-amine, N-(1-benzyl-4-piperidinyl)-1H-indazole-5-amine dihydrochloride, 4-[2-(2,3,4,5,6-pentafluorophenyl)acryloyl]cinnamic acid and fasudil hydrochloride.

19. (Withdrawn) The method according to claim 15, wherein the ROCK inhibitor is selected from the group consisting of 2-chloro-6,7-dimethoxy-N-[5-1H-indazolyl]quinazoline-4-amine, N-(1-benzyl-4-piperidinyl)-1H-indazole-5-amine dihydrochloride, 4-[2-(2,3,4,5,6-pentafluorophenyl)acryloyl]cinnamic acid and fasudil hydrochloride.

20. (Withdrawn) The method according to claim 16, wherein the ROCK inhibitor is selected from the group consisting of 2-chloro-6,7-dimethoxy-N-[5-1H-indazolyl]quinazoline-4-amine, N-(1-benzyl-4-piperidinyl)-1H-indazole-5-amine dihydrochloride, 4-[2-(2,3,4,5,6-pentafluorophenyl)acryloyl]cinnamic acid and fasudil hydrochloride.